Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in women’s health.

Clairity Breast, a product of Clairity Inc., is the first FDA-authorized, image-based artificial intelligence tool designed to assess a woman’s future risk of breast cancer. This AI technology derives the score directly and exclusively from a woman’s mammogram, transforming a diagnostic tool into a predictive one.

Feb. 12, 2026 — Agfa HealthCare continued its strong business momentum across the U.S. market, as health systems expand their use of scalable, cloud-based Enterprise Imaging solutions that support clinical efficiency, clinical collaboration and organizational growth.

Feb. 19, 2026 — GE HealthCare recently announced 510(k) clearance of three new magnetic resonance (MR) innovations with the U.S. Food and Drug Administration (FDA): SIGNA Sprint with Freelium¹, a 1.5T sealed magnet MRI system; SIGNA Bolt², an advanced 3T MRI scanner; and SIGNA One³, an AI-driven ecosystem of workflow solutions designed to help reduce inefficiencies and support MRI exams from plan to scan and beyond.

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy System, the industry's first system designed to be positioned in the MRI scanner room, at the patient's side during a breast biopsy procedure. This enhances clinician coordination, improves communication and keeps the focus on patient care by bringing the vacuum-assisted breast biopsy device directly into the room.

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast imaging radiologists, putting pressure on access and turnaround times nationwide.